Recombinant Human Poliovirus receptor (PVR)

What is the Recombinant Human Poliovirus Receptor (PVR)?

Recombinant Human Poliovirus Receptor (PVR), also known as CD155, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It functions as the cellular receptor for poliovirus entry into human cells and plays a critical role in mediating cell attachment to the extracellular matrix molecule vitronectin . The recombinant form is produced through molecular cloning and protein expression systems, typically including the extracellular domain with various tags for purification and detection purposes. Commercially available recombinant PVR proteins often contain specific amino acid sequences (such as Gly27-Asn343) with purification tags (like His-tag or C-Myc/DDK) to facilitate research applications .

What is the molecular structure of PVR and how does it relate to function?

PVR is structurally characterized as a type I transmembrane glycoprotein with multiple domains. The full-length protein consists of three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail. For research purposes, recombinant PVR typically contains the extracellular portion responsible for virus binding.

The specific binding site for poliovirus has been elucidated through cryo-electron microscopy and image reconstruction of receptor-PV1/M complexes, which revealed that the receptor binds to the 'wall' of surface protrusions surrounding the 'canyon' - a depressive surface in the viral capsid . This binding location differs from that of rhinoviruses, whose receptors bind directly in the canyon region. This structural difference explains the distinct binding kinetics and thermodynamic properties observed between PVR-poliovirus and rhinovirus-receptor interactions .

How do expression systems affect recombinant PVR quality and functionality?

The choice of expression system significantly impacts the quality and functionality of recombinant PVR. Common expression hosts include HEK293T cells, which provide proper mammalian post-translational modifications essential for correct protein folding and glycosylation . When evaluating expression systems for PVR production, researchers should consider:

• Post-translational modifications: Mammalian systems like HEK293T provide glycosylation patterns similar to native human PVR, critical for proper folding and function

• Protein yield: Expression levels vary between systems, affecting final protein concentration

• Protein solubility: Different systems may produce varying levels of soluble versus aggregated protein

• Functional activity: The expression system can impact the receptor's ability to bind poliovirus

Expression in HEK293T cells typically yields a predicted molecular weight of approximately 39.1 kDa for recombinant PVR with common tags . Researchers should validate the functionality of the expressed protein through binding assays with poliovirus or other known ligands.

How do binding kinetics differ between PVR interactions with poliovirus versus rhinoviruses?

Surface plasmon resonance studies have revealed significant differences in binding kinetics between PVR-poliovirus interactions and rhinovirus-receptor interactions. Specifically, PVR binding to human poliovirus type 1 (PV1/M) occurs with faster association and dissociation rates compared to the binding between rhinovirus receptors and HRV3 or HRV16 .

These kinetic differences are summarized in the table below:

The faster association rate observed with PVR-PV1/M suggests a more accessible binding site on the poliovirus capsid compared to rhinoviruses. This accessibility difference correlates with the structural finding that PVR binds to the 'wall' of surface protrusions surrounding the canyon rather than within the canyon itself .

What methodologies are most effective for studying PVR-mediated virus uncoating?

Studying PVR-mediated virus uncoating requires a multifaceted approach combining biophysical, structural, and functional techniques. Effective methodologies include:

• Thermodynamic analysis: Measures the energetics of receptor binding and its impact on viral capsid stability. Studies have demonstrated that receptor interaction with PV1/M is more disruptive than with rhinoviruses, correlating with differences in uncoating mechanisms .

• Cryo-electron microscopy: Provides structural insights into conformational changes that occur during receptor binding and the initiation of uncoating. This technique has been instrumental in identifying the binding location of PVR on the poliovirus capsid .

• Fluorescence-based uncoating assays: Utilizes fluorescent dyes that interact with viral RNA upon capsid destabilization to monitor the uncoating process in real-time.

• Bioassays using recombinant PVR: Enables detection of polioviruses and assessment of receptor-mediated uncoating, as demonstrated in studies utilizing recombinant poliovirus receptor for direct virus detection .

When designing experiments to study uncoating, researchers should consider the concentration and purity of recombinant PVR (typically >80% as determined by SDS-PAGE) , buffer conditions (commonly 25 mM Tris-HCl, 100 mM glycine, pH 7.3, with 10% glycerol) , and appropriate controls to distinguish receptor-mediated effects from spontaneous uncoating events.

How can structural biology techniques enhance our understanding of PVR-virus complexes?

Structural biology techniques offer critical insights into the molecular details of PVR-virus interactions. Cryo-electron microscopy and image reconstruction have been particularly valuable in revealing that PVR binds to the 'wall' of surface protrusions surrounding the 'canyon' on the poliovirus capsid . This finding was unexpected given that rhinovirus receptors typically bind within the canyon.

Researchers seeking to apply structural biology techniques to PVR-virus complexes should consider:

• Sample preparation: Ensuring high-purity recombinant PVR (>80% as determined by SDS-PAGE) and homogeneous virus preparations is critical for structural studies.

• Complex formation: Optimizing conditions for stable complex formation between PVR and virus particles before structural analysis.

• Complementary techniques: Combining cryo-EM with other methods like X-ray crystallography or hydrogen-deuterium exchange mass spectrometry provides a more comprehensive understanding of binding interfaces and conformational changes.

• Resolution considerations: Higher resolution structures reveal atomic-level details of interactions, but even intermediate-resolution maps can provide valuable information about binding locations and gross conformational changes.

These techniques continue to advance our understanding of how structural differences in receptor binding correlate with functional outcomes like viral entry and uncoating efficiency.

What are the optimal purification strategies for recombinant PVR in research settings?

Effective purification of recombinant PVR typically involves a multi-step process designed to maximize yield, purity, and functionality. Based on established protocols, researchers should consider the following approach:

• Affinity chromatography: Recombinant PVR with tags (His-tag, DDK/FLAG) can be captured using specific affinity columns. For example, anti-DDK affinity columns have been effectively used as the first purification step .

• Conventional chromatography: Following initial capture, additional chromatography steps such as ion exchange and size exclusion chromatography help remove contaminants and aggregates .

• Quality assessment: Purity should be assessed using SDS-PAGE with Coomassie blue staining, with >80% purity being suitable for most research applications .

• Concentration determination: Protein concentration can be accurately determined using microplate BCA method, with typical research-grade preparations exceeding 0.05 μg/μL .

• Buffer conditions: Optimal storage buffer typically contains 25 mM Tris-HCl, 100 mM glycine, pH 7.3, with 10% glycerol . These conditions maintain protein stability while preventing aggregation.

For cell culture applications, researchers should filter the purified protein before use, noting that some protein loss during filtration is expected . Long-term storage at -80°C is recommended, with avoidance of repeated freeze-thaw cycles to preserve functionality .

How can surface plasmon resonance (SPR) be optimized for studying PVR-virus interactions?

Surface plasmon resonance provides valuable quantitative data on the kinetics and affinity of PVR-virus interactions. Previous research has successfully employed SPR to demonstrate that PVR binding to poliovirus exhibits faster association and dissociation rates compared to rhinovirus-receptor interactions . To optimize SPR experiments for studying PVR-virus interactions, researchers should:

• Immobilization strategy: Consider whether to immobilize the virus or the receptor. Immobilizing recombinant PVR often provides more consistent results while allowing multiple virus serotypes to be tested on the same chip.

• Surface density: Control the density of immobilized ligand to minimize mass transport limitations and steric hindrance that can affect kinetic measurements.

• Buffer optimization: Develop a running buffer that maintains both PVR and virus stability while minimizing non-specific interactions. PBS with 0.005% surfactant is often suitable.

• Reference surfaces: Include appropriate reference surfaces (e.g., irrelevant protein) to account for non-specific binding and bulk refractive index changes.

• Regeneration conditions: Establish mild regeneration conditions that remove bound analyte without damaging the immobilized ligand, enabling multiple measurement cycles.

• Data analysis: Apply appropriate binding models (1:1 Langmuir, heterogeneous ligand, etc.) based on the expected interaction mechanism between PVR and virus particles.

By carefully optimizing these parameters, researchers can obtain reliable kinetic constants (ka, kd) and equilibrium dissociation constants (KD) that accurately reflect the PVR-virus interaction.

What techniques are recommended for functional validation of recombinant PVR?

Functional validation of recombinant PVR is essential to ensure that the produced protein retains its native binding and biological properties. Recommended techniques include:

• Bioassay for poliovirus detection: Recombinant PVR has been successfully used for direct detection of polioviruses, providing a functional readout of virus-receptor interaction .

• Virus neutralization assays: Pre-incubation of virus with soluble recombinant PVR can inhibit infection by competing with cellular receptors, confirming functional binding.

• Cell attachment assays: Since PVR mediates cell attachment to extracellular matrix molecules like vitronectin , assessing this function can provide additional validation.

• Thermostability studies: Measuring the impact of recombinant PVR on virus particle stability using thermal or chemical denaturation assays can confirm functional interaction, as receptor binding typically alters capsid stability .

• Surface plasmon resonance: Quantitative binding assays measuring association and dissociation rates compared to reference standards can verify proper folding and binding capacity .

A comprehensive validation approach should incorporate multiple techniques to assess different aspects of PVR functionality, ensuring that the recombinant protein accurately represents the native receptor's properties for research applications.

How is recombinant PVR utilized in poliovirus detection and serotyping assays?

Recombinant PVR has proven valuable for the direct detection of polioviruses in research and diagnostic settings. A significant application was demonstrated in a 2021 study where recombinant poliovirus receptor was employed in a bioassay system for poliovirus detection . The methodology involves:

• Capture phase: Recombinant PVR (typically His-tagged or similar constructs) is immobilized on a solid surface through affinity interactions .

• Sample application: Clinical or environmental samples potentially containing poliovirus are applied to the PVR-coated surface.

• Detection system: Bound viruses are detected using specific antibodies or molecular methods, with the specificity provided by the natural affinity of PVR for polioviruses.

• Serotyping capability: The assay can distinguish between poliovirus serotypes based on their differential binding characteristics to PVR.

This approach offers several advantages over traditional cell culture-based methods, including:

• Reduced time to results (hours versus days)

• No requirement for specialized cell culture facilities

• Potential for integration into automated or field-deployable systems

• Direct detection of viral particles rather than infectious virus

For researchers implementing such assays, the quality and functional activity of the recombinant PVR is critical, with recommended purity of >80% as determined by SDS-PAGE and proper validation of binding capacity .

How does understanding PVR-poliovirus interactions contribute to antiviral therapeutic development?

The detailed characterization of PVR-poliovirus interactions provides valuable insights for antiviral therapeutic development through several mechanisms:

• Receptor mimetics: Knowledge of the binding interface between PVR and poliovirus enables the design of soluble receptor decoys or small molecules that mimic receptor binding. The faster association and dissociation rates observed between PVR and PV1/M compared to rhinovirus-receptor interactions inform the kinetic properties required for effective decoy molecules.

• Allosteric inhibitors: Structural studies showing that PVR binds to the 'wall' of surface protrusions surrounding the 'canyon' identify potential allosteric sites that could be targeted by small-molecule inhibitors to prevent receptor binding or virus uncoating.

• Uncoating inhibitors: The more disruptive receptor interaction with PV1/M compared to rhinoviruses suggests that compounds stabilizing the capsid specifically against PVR-induced conformational changes could effectively inhibit infection.

• Structure-based design: Cryo-electron microscopy reconstructions of receptor-PV1/M complexes provide templates for structure-based drug design targeting the PVR-binding site or nearby regions.

Researchers pursuing antiviral development should consider the thermodynamic and kinetic aspects of PVR-poliovirus interactions, as these properties directly influence the efficacy of competitive inhibitors. Additionally, understanding the specific structural elements of PVR required for virus binding (e.g., Gly27-Asn343 region) allows for focused design of mimetic compounds targeting essential interaction surfaces.

What are the experimental design considerations for investigating cross-reactivity between PVR and related viruses?

When designing experiments to investigate potential cross-reactivity between PVR and viruses beyond poliovirus, researchers should consider several critical factors:

• Protein constructs: Utilize well-defined recombinant PVR constructs with consistent boundaries (e.g., Gly27-Asn343) and appropriate tags for detection and purification. Consider multiple constructs representing different domains to identify specific regions involved in cross-reactivity.

• Comparative binding studies: Implement surface plasmon resonance or similar quantitative binding assays to directly compare association and dissociation rates between PVR and various viruses, as was done for poliovirus versus rhinoviruses . This provides kinetic signatures that may correlate with biological relevance.

• Structural analysis: Apply cryo-electron microscopy and image reconstruction techniques to visualize binding interfaces between PVR and potential cross-reactive viruses, comparing these to the established binding site on poliovirus (the 'wall' of surface protrusions surrounding the 'canyon') .

• Functional validation: Assess whether PVR-virus interactions lead to functional outcomes such as:

  • Virus uncoating (measured thermodynamically)

  • Inhibition of cell infection in competition assays

  • Changes in virus particle stability

• Controls and standards: Include established PVR-poliovirus interactions as positive controls and known non-interacting viruses as negative controls.

The experimental approach should account for the faster association and dissociation rates observed with PVR-poliovirus interactions compared to other virus-receptor pairs , which may necessitate adjusted instrument settings or sampling rates for accurate measurement of cross-reactive binding events.

What are common challenges in recombinant PVR expression and how can they be addressed?

Researchers working with recombinant PVR may encounter several challenges during expression and purification. Based on established protocols and commercial production practices, the following solutions are recommended:

For researchers seeking consistent results, maintaining protein quality through proper handling is essential. After purification, aliquot the protein to avoid repeated freeze-thaw cycles and store at -80°C for long-term stability . When using in cell culture applications, filter the protein before use, acknowledging that some loss during filtration is expected .

How can researchers optimize experimental conditions for studying thermodynamics of PVR-virus interactions?

Optimizing experimental conditions for thermodynamic analysis of PVR-virus interactions requires careful consideration of multiple parameters. Based on previous research showing thermodynamic differences between PVR-poliovirus and rhinovirus-receptor interactions , the following optimization strategies are recommended:

• Buffer composition:

  • Maintain physiological pH (7.2-7.4) to represent in vivo conditions

  • Include stabilizing agents that don't interfere with binding (e.g., glycerol up to 10%)

  • Control ionic strength to minimize non-specific electrostatic interactions

  • Consider using 25 mM Tris-HCl, 100 mM glycine, pH 7.3 as a starting point

• Temperature range:

  • Perform experiments across physiologically relevant temperatures (4-37°C)

  • Include temperature gradients to calculate entropy and enthalpy contributions

  • Ensure equipment calibration within the selected temperature range

• Concentration determination:

  • Accurately determine protein concentration using microplate BCA method or similar

  • Verify virus particle concentration using both physical (absorbance) and biological (infectivity) measurements

  • Account for potential inactive fraction of both receptor and virus preparations

• Data analysis:

  • Apply appropriate binding models based on expected stoichiometry

  • Consider heterogeneity in virus preparations when interpreting results

  • Use global fitting across multiple concentrations and temperatures for robust parameter estimation

• Controls:

  • Include non-binding receptor or virus mutants as negative controls

  • Use well-characterized ligand-receptor pairs as reference standards

  • Perform parallel experiments with rhinovirus-receptor systems for direct comparison

By systematically optimizing these parameters, researchers can obtain reliable thermodynamic data that accurately reflects the energetic profile of PVR-virus interactions, providing insights into the mechanistic basis of receptor-mediated uncoating and viral entry.